YS2302018 was discovered by CSPC and has been shown to effectively prevent the formation of Lp(a).

Tirzepatide is not Lilly’s only contender in this field; its small-molecule agonist orforglipron also met primary endpoints in studies and is poised for regulatory submission and potential approval.

F.Hoffmann-La Roche(Roche) disclosed two patent applications, WO2025093625A1 and WO2025104149A1, covering a series of novel macrocyclic KRAS G12C inhibitors.

Eisbach Bio GmbH has disclosed two patent applications primarily focused on the use of ALC1 inhibitors in cancer treatment: WO2025088087A1 and WO2025088175A1.

A recent Monte Rosa patent application (WO2025090727) covers eight compounds and reveals the possible structure of MRT-9643 (CDK2 MGD) (compound 6).

Suzetrigine is the first non-opioid novel pain medication approved in over two decades for pain management; however, its efficacy appears to be limited.

Sarcopenia, a condition characterized by age - related muscle loss and strength decline, is a growing health concern.

Beyond the drugs targeting specific pathways like the Activin - ActRII - ActRI pathway, there are other medications being developed for obesity and muscle - wasting disorders.

The discovery of INHBE and ALK7 as potential drug targets has opened up new avenues in the development of therapies for obesity and metabolic disorders.

By conducting in - depth searches in relevant databases, the development of drugs targeting MSTN/GDF8 and bone morphogenetic proteins (BMPs) has been revealed.

Through comprehensive searches in the Patsnap Synapse database, it has been found that the key drugs targeting ActRII mainly consist of fusion proteins and monoclonal antibodies.

In the pursuit of treating muscle - related diseases and achieving effective weight management with the goal of “fat loss with muscle gain”.